ORCHARD THERAPEUTICS (EUROPE) LIMITED
Get an alert when ORCHARD THERAPEUTICS (EUROPE) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-02-28 (in 9mo)
Last made up 2026-02-14
Watchouts
Cash
£7M
-21.6% vs 2023
Net assets
-£63M
-40.7% vs 2023
Employees
107
+2.9% vs 2023
Profit before tax
-£112M
-45.3% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Name history
Renamed 2 times since incorporation
- ORCHARD THERAPEUTICS (EUROPE) LIMITED 2018-10-29 → present
- ORCHARD THERAPEUTICS LIMITED 2015-11-03 → 2018-10-29
- NEWINCCO 1387 LIMITED 2015-09-02 → 2015-11-03
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £15,797,068 | £26,356,723 | |
| Operating profit | -£83,612,618 | -£106,337,935 | |
| Profit before tax | -£77,088,239 | -£112,002,143 | |
| Net profit | -£74,245,347 | -£91,948,834 | |
| Cash | £8,798,990 | £6,901,422 | |
| Total assets less current liabilities | -£32,174,902 | -£62,357,847 | |
| Net assets | -£44,838,039 | -£63,107,847 | |
| Equity | -£44,838,039 | -£63,107,847 | |
| Average employees | 104 | 107 | |
| Wages | £13,277,314 | £19,848,645 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -529.3% | -403.5% | |
| Net margin | -470.0% | -348.9% | |
| Return on capital employed | 259.9% | 170.5% | |
| Gearing (liabilities / total assets) | 168.1% | 142.8% | |
| Current ratio | 0.26x | 0.54x | |
| Interest cover | -299.35x | -17.93x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period of at least 12 months from the date of approval of the financial statements and consider this an appropriate basis for the preparation of the financial statements.”
Group structure
- ORCHARD THERAPEUTICS (EUROPE) LIMITED · parent
- Orchard Therapeutics North America 100%
- Orchard Therapeutics Netherlands B.V. 100%
- Orchard Therapeutics (Italy) S.r.l 100%
- Orchard Therapeutics (France) SAS 100%
- Orchard Therapeutics (Germany) GmbH 100%
- Orchard Therapeutics (Switzerland) GmbH 100%
- Orchard Therapeutics (Sweden) AB 100%
Significant events
- “On 24 January 2024, the Company’s parent company Orchard Therapeutics Plc was acquired by Kyowa Kirin International Plc, as a nominee of Kyowa Kirin Co., Ltd.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 19 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| YORK, Christopher Tappan | Secretary | 2022-02-28 | — | — |
| ELLIS, Jonathan Henry Welbore, Dr | Director | 2025-09-10 | Mar 1967 | British |
| FUJII, Yasuo | Director | 2025-09-10 | May 1964 | Japanese |
| GASPAR, Hubert Baburaj, Dr | Director | 2016-02-06 | Nov 1963 | British |
| MULLICK, Abdul Hafeez | Director | 2025-09-10 | May 1967 | British |
| YAMASHITA, Takeyoshi | Director | 2025-09-10 | Nov 1961 | Japanese |
Show 19 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ILETT, John Edward | Secretary | 2018-04-11 | 2022-02-28 |
| OLSWANG COSEC LIMITED | Corporate Secretary | 2015-09-02 | 2015-11-02 |
| ANDREWS, Martin | Director | 2018-04-11 | 2018-07-17 |
| AUSPITZ, Benjamin Adam | Director | 2016-02-06 | 2018-04-11 |
| BECK, Joanne | Director | 2018-07-01 | 2018-10-19 |
| DUNOYER, Marc | Director | 2018-06-06 | 2018-10-19 |
| ELLIS, Jonathan Henry Welbore, Dr | Director | 2018-07-17 | 2018-10-19 |
| FANG SONG, Hong | Director | 2017-09-06 | 2018-10-19 |
| GERAGHTY, James | Director | 2018-06-04 | 2018-10-19 |
| ILETT, John Edward | Director | 2018-10-10 | 2022-02-28 |
| MACKIE, Christopher Alan | Director | 2015-09-02 | 2015-11-02 |
| PASTEUR, Alexander, Dr | Director | 2015-11-02 | 2018-10-19 |
| ROTHERA, Mark | Director | 2017-09-04 | 2020-03-17 |
| ROWLAND JR, Charles | Director | 2018-06-01 | 2018-10-19 |
| WANG, Elise | Director | 2018-08-02 | 2018-10-19 |
| WILLIAMS, Chris | Director | 2016-02-06 | 2016-06-30 |
| WISE, Helen, Dr | Director | 2016-06-30 | 2016-12-23 |
| OLSWANG DIRECTORS 1 LIMITED | Corporate Director | 2015-09-02 | 2015-11-02 |
| OLSWANG DIRECTORS 2 LIMITED | Corporate Director | 2015-09-02 | 2015-11-02 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Kyowa Kirin International Plc | Corporate entity | Shares 75–100% | 2025-09-10 | Active |
| Orchard Therapeutics Limited | Legal person | Shares 75–100%, Voting 75–100% | 2018-10-19 | Ceased 2025-09-10 |
Filing timeline
Last 20 of 120 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-27 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-11-10 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-11-10 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-10-29 | AA | accounts | Accounts with accounts type full | |
| 2025-09-25 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-25 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-25 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-25 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-20 | PSC06 | persons-with-significant-control | Change to a person with significant control | |
| 2025-02-20 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-07 | AA | accounts | Accounts with accounts type full | |
| 2024-02-26 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-02-26 | SH01 | capital | Capital allotment shares | |
| 2023-08-02 | AA | accounts | Accounts with accounts type audit exemption subsiduary | |
| 2023-07-03 | PARENT_ACC | accounts | Legacy | |
| 2023-07-03 | GUARANTEE2 | other | Legacy | |
| 2023-07-03 | AGREEMENT2 | other | Legacy | |
| 2023-03-15 | SH01 | capital | Capital allotment shares | |
| 2023-02-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-03 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 4
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+66.8%
£15,797,068 £26,356,723
-
Cash
-21.6%
£8,798,990 £6,901,422
-
Net assets
-40.7%
-£44,838,039 -£63,107,847
-
Employees
+2.9%
104 107
-
Operating profit
-27.2%
-£83,612,618 -£106,337,935
-
Profit before tax
-45.3%
-£77,088,239 -£112,002,143
-
Wages
+49.5%
£13,277,314 £19,848,645
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers